Fabrazyme biosimilar?

Short answer: There is no FDA- or EMA-approved Fabrazyme (agalsidase beta) biosimilar available currently.

What that means:
- Fabrazyme is agalsidase beta, an enzyme replacement therapy for Fabry disease.
- A biosimilar would be another product designed to be highly similar to Fabrazyme in structure, function, safety, and efficacy, and it would need regulatory approval. As of now, none has been approved in major markets.
- Developers may be researching or conducting trials, but nothing has earned approval yet.

A few practical notes:
- The closest approved enzyme replacement therapy you might encounter is agalsidase alfa (Replagal), which is a different form (agalsidase alfa) and not interchangeable with agalsidase beta.
- If a biosimilar did become available, dosing and administration would be guided by regulatory-approved labeling and your clinician, and “interchangeable” status (which allows pharmacy-level substitution) is a separate, stricter designation in the U.S.
- If you’re considering cost or access issues, talk to your healthcare provider about options, including whether a biosimilar might be appropriate in the future and what monitoring would be needed.

If you’d like, I can look up the latest regulatory status for Fabrazyme biosimilars in the US/EU and summarize any candidates in development.